期刊文献+

阿立哌唑与利培酮对男性精神分裂症患者性功能、甲状腺素水平及糖脂代谢的影响 被引量:8

Effects of Aripiprazole and Risperidone on Sexual Function,Thyroxine Level and Glycolipid Metabolism in Male Schizophrenic Patients
原文传递
导出
摘要 目的:探讨阿立哌唑与利培酮对男性精神分裂症患者性功能、甲状腺素水平及糖脂代谢的影响。方法:选取我院于2016年1月至2017年10月期间收治的92例精神分裂症患者。根据数表法将患者随机分为对照组(n=46)与研究组(n=46),对照组给予利培酮治疗,研究组给予阿立哌唑治疗,两组均治疗8周。观察两组患者临床疗效、性功能、糖脂代谢、甲状腺素水平。结果:研究组患者临床总有效率为84.78%(39/46),高于对照组的78.26%(36/46),但差异无统计学意义(P>0.05)。研究组治疗前后性欲、性唤起以及性高潮比较差异无统计学意义(P>0.05);对照组治疗后上述指标低于治疗前和研究组(P<0.05)。研究组治疗前后三碘甲状腺原氨酸(T3)、甲状腺素(T4)、游离三碘甲状腺原氨酸(FT3)比较差异无统计学意义(P>0.05),游离甲状腺素(FT4)低于治疗前(P<0.05);对照组治疗后T4、FT3以及FT4低于治疗前和研究组(P<0.05)。研究组治疗前后总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、空腹血糖(FPG)以及餐后2 h血糖(2hPG)比较差异无统计学意义(P>0.05);对照组治疗后TG、HDL-C、FPG以及2hPG高于治疗前和研究组(P<0.05)。结论:阿立哌唑对男性精神分裂症患者的性功能、甲状腺素水平及糖脂代谢影响较小,与利培酮均具有较好的治疗效果,可做进一步推广应用。 Objective:To investigate the effects of aripiprazole and risperidone on sexual function,thyroxine level and glycolipid metabolism in male schizophrenic patients.Methods:92 cases of schizophrenia who were treated in our hospital from January 2016 to October 2017 were selected,the patients were divided into control group(n=46) and study group(n=46) according to the number table method.The control group was treated with risperidone,and the study group was treated with aripiprazole,the two groups were treated for 8 weeks.The clinical efficacy,sexual function,glycolipid metabolism and thyroxine level were observed between the two groups.Results:The total clinical effective rate of the patients in the study group was 84.78%(39/46),which was higher than 78.26%(36/46) of the control group,but the difference was not statistically significant(P〉0.05).There were no significant differences in sexual desire,sexual arousal and orgasm between the study group before and after treatment(P〉0.05),the above indexes in the control group were lower than those before treatment and the study group(P〈0.05).There was no significant difference in the triiodothyronine(T3),thyroxine(T4) and free triiodothyronine(FT3) in the study group before and after treatment(P〉0.05),free thyroxine(FT4) was lower than before treatment(P〈0.05),after treatment,T4,FT3 and FT4 in the control group were lower than before treatment and in the study group(P〈0.05).There were no significant differences in total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),fasting blood glucose(FPG) and postprandial 2 H blood glucose(2 hPG) in the study group before and after treatment(P〉0.05).The TG,HDL-C,FPG and 2 hPG in the control group after treatment were higher than those before treatment and study group(P〈0.05).Conclusion:Aripiprazole has less effect on sexual function,thyroxine level and glycolipid metabolism in male schizophrenic patients,and risperidone has good therapeutic effect and can be used for further promotion and application.
作者 胡曼娜 阿地拉.阿吉 张丞 马瑞 沈小琴 HU Man-na;Adila ·Aji;ZHANG Cheng;MA Rui;SHEN Xiao-qin(Department of Psychiatry,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi,Xinjiang,830000,China)
出处 《现代生物医学进展》 CAS 2018年第18期3546-3549,共4页 Progress in Modern Biomedicine
基金 新疆维吾尔自治区人民医院科研项目(20160107)
关键词 阿立哌唑 利培酮 男性 精神分裂症 性功能 甲状腺素 糖脂代谢 Aripiprazole Risperidone Male Schizophrenic Sexual function Thyroxine level Glycolipid metabolism
  • 相关文献

参考文献2

二级参考文献20

  • 1Kristensen D, Hageman I, Bauer J, et al. Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy [J]. J ECT,2013, 29(4): 271-276.
  • 2Sasaki T, Hashimoto T, Niitsu T, et al. Treatment of refractory catatonic schizophrenia with low dose aripiprazole [J]. Ann Gen Psychiatry, 2012, 11(1): 12-13.
  • 3Melnik T, Soares BG, Puga ME, et al. Efficacy and safety of atypical antipsychotic drugs (quetiapine,risperidone,aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia:overview of systematic reviews [J]. Sao Panlo Med J, 2010, 128(3): 141-166.
  • 4Asenjo Lobos C, Komossa K, et al. Clozapine versus other atypical antipsychotics for schizophrenia [J]. Cochrane Database Syst Rev, 2010, 10(11): 6633-6634.
  • 5Grover S, Dutt A, Chakrabarty K, et al. Treatment resistant non-catatonic mutism in schizophrenia responding to a combination of continuation electroconvulsive therapy and neuroleptics [J]. Ind Psychiatry J, 2012, 21(1): 69-71.
  • 6Schimmelmann BG, Schmidt S J, Carbon M, et al. Treatment of adolescents with early-onset schizophrenia spectrum disorders:in search of a rational, evidence-informed approach [J]. Curt Opin Psychiatry, 2013, 26(2): 219-230.
  • 7Chang TS, Tsai CK, Liang CS, et al. Clozapine use in refractory schizophrenia comorbid with acute myeloid leukemia [J]. Psychosomatics, 2015, 56(3): 302-305.
  • 8Bumb JM, Enning F, Leweke FM, et al. Drug repurposing and emerging adjunctive treatments for schizophrenia [J]. Expert Opin Pharmacother, 2015, 16(7): 1049-1067.
  • 9Nakajima S, Takeuchi H, Plitman E, et al. Neuroimaging findings in treatment-resistant schizophrenia:A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia [J]. Schizophr Res, 2015, 164(1): 164-175.
  • 10Usta NG, Poyraz CA, Aktan M, et al.Clozapine treatment of refractory schizophrenia during essential chemotherapy:a case study and mini review of a clinical dilemma [J]. Ther Adv Psychopharmacol, 2014, 4(6): 276-281.

共引文献410

同被引文献67

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部